Trial Profile
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Dasatinib (Primary) ; Sunitinib (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 08 Dec 2023 Status changed from active, no longer recruiting to completed.
- 14 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.